Skip to main content

Table 2 HRQoL scores for adults over the course of the study

From: Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

  U.S. general population [8, 9] N Baseline n End of part 1 Change from baseline at end of part 1 n End of part 3 Change from baseline at end of part 3
FACIT-F 43.6 26 27.4 ± 13.0 24 40.6 ± 12.0 13.5a 26 39.5 ± 14.7 12.2a
SF-36 PCS 50.0 23 41.0 ± 9.6 20 51.0 ± 8.3 9.5a 22 48.5 ± 12.6 8.2a
SF-36 MCS 50.0 23 43.1 ± 12.3 20 47.3 ± 13.4 3.6 22 48.9 ± 12.4 6.3a
HAQ NA 26 0.41 ± 0.63 25 0.17 ± 0.40 -0.26a 26 0.27 ± 0.45 -0.14
  1. Values are expressed as mean ± SD. ap value < 0.05. FACIT-F, functional assessment of chronic illness therapy- fatigue; HAQ, health assessment questionnaire; MCS, mental component summary; NA, not available; PCS, physical component summary; SF-36, 36-item Short-Form Health Survey.